184 related articles for article (PubMed ID: 37604640)
21. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
[TBL] [Abstract][Full Text] [Related]
22. High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.
Kortekaas KE; Santegoets SJ; Abdulrahman Z; van Ham VJ; van der Tol M; Ehsan I; van Doorn HC; Bosse T; van Poelgeest MIE; van der Burg SH
J Immunother Cancer; 2019 Sep; 7(1):236. PubMed ID: 31481117
[TBL] [Abstract][Full Text] [Related]
23. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
[TBL] [Abstract][Full Text] [Related]
24. VISTA blockade alleviates immunosuppression of MDSCs in oral squamous cell carcinoma.
Liu J; Lin WP; Xiao Y; Yang QC; Bushabu Fidele N; Yu HJ; Sun ZJ
Int Immunopharmacol; 2023 Dec; 125(Pt A):111128. PubMed ID: 37907049
[TBL] [Abstract][Full Text] [Related]
25. [Application value of whole exon sequencing and immune related indicators in the precision treatment of oral squamous cell carcinoma].
Xie S; Cai ZG; Shan XF
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Aug; 55(4):697-701. PubMed ID: 37534654
[TBL] [Abstract][Full Text] [Related]
26. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
27. Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck.
El Baroudi M; Machiels JP; Schmitz S
Cancer Biol Ther; 2017 Oct; 18(10):775-782. PubMed ID: 28886272
[TBL] [Abstract][Full Text] [Related]
28. Lipid droplets-related Perilipin-3: potential immune checkpoint and oncogene in oral squamous cell carcinoma.
He Y; Liu L; Dong Y; Zhang X; Song Y; Jing Y; Ni Y; Wang Y; Wang Z; Ding L
Cancer Immunol Immunother; 2024 Mar; 73(5):78. PubMed ID: 38554152
[TBL] [Abstract][Full Text] [Related]
29. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
[TBL] [Abstract][Full Text] [Related]
30. Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India.
Basu B; Chakraborty J; Chandra A; Katarkar A; Baldevbhai JRK; Dhar Chowdhury D; Ray JG; Chaudhuri K; Chatterjee R
Clin Epigenetics; 2017; 9():13. PubMed ID: 28174608
[TBL] [Abstract][Full Text] [Related]
31. NRF2 Activation in Trp53;p16-deficient Mice Drives Oral Squamous Cell Carcinoma.
Hamad SH; Sellers RS; Wamsley N; Zolkind P; Schrank TP; Major MB; Weissman BE
Cancer Res Commun; 2024 Feb; 4(2):487-495. PubMed ID: 38335300
[TBL] [Abstract][Full Text] [Related]
32. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
33. Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer.
Sano D; Xie TX; Ow TJ; Zhao M; Pickering CR; Zhou G; Sandulache VC; Wheeler DA; Gibbs RA; Caulin C; Myers JN
Clin Cancer Res; 2011 Nov; 17(21):6658-70. PubMed ID: 21903770
[TBL] [Abstract][Full Text] [Related]
34. Tumor-infiltrating ICOS
Kajikawa H; Hirata M; Haruna M; Ueyama A; Hirose K; Kawashima A; Iwahori K; Matsunaga K; Toyosawa S; Uzawa N; Wada H
Anticancer Res; 2022 May; 42(5):2383-2393. PubMed ID: 35489733
[TBL] [Abstract][Full Text] [Related]
35. A bioinformatic analysis of the role of TP53 status on the infiltration of CD8+ T cells into the tumor microenvironment.
El-Arabey AA; Abdel-Hamied HE; Awadalla ME; Alosaimi B; Almanaa TN; Al-Shouli ST; Modafer YA; Alhamdi HW; Abdalla M
Braz J Med Biol Res; 2023; 56():e12970. PubMed ID: 37878888
[TBL] [Abstract][Full Text] [Related]
36. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
Front Immunol; 2022; 13():969034. PubMed ID: 36466881
[TBL] [Abstract][Full Text] [Related]
37. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.
Zhou G; Liu Z; Myers JN
J Cell Biochem; 2016 Dec; 117(12):2682-2692. PubMed ID: 27166782
[TBL] [Abstract][Full Text] [Related]
38. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.
Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS
Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487
[TBL] [Abstract][Full Text] [Related]
39. Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers.
Chen SMY; Popolizio V; Woolaver RA; Ge H; Krinsky AL; John J; Danis E; Ke Y; Kramer Y; Bian L; Nicklawsky AG; Gao D; Liu S; Chen Z; Wang XJ; Wang JH
J Exp Clin Cancer Res; 2022 Apr; 41(1):123. PubMed ID: 35366939
[TBL] [Abstract][Full Text] [Related]
40. TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection.
Klinakis A; Rampias T
EBioMedicine; 2020 Aug; 58():102905. PubMed ID: 32739866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
